ClinicalTrials.gg
RecruitingNCT07047092Updated Jun 9, 2026

Non-invasive Ventilation or CPAP in OSA-COPD Following Admission for an Acute Hypercapnic Respiratory Failure

A Phase 3 interventional study of Non-invasive Ventilation (NIV) and Continous Positive Airway Pressure (CPAP) in Chronic Obstructive Pulmonary Disease Exacerbation and Obstructive Sleep Apnea Exacerbation, sponsored by Assistance Publique - Hôpitaux de Paris. Recruiting at 1 site in France. Open to participants aged 18 Years to 84 Years. Per ClinicalTrials.gov, last updated 2026-06-09.

Sponsored by Assistance Publique - Hôpitaux de Paris · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2026; still recruiting 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
386
Allocation
Randomized
Ages
18 Years to 84 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 21 studies in Pulmonary Disease, Chronic Obstructive by Assistance Publique - Hôpitaux de Paris — 7 open to participants now, 8 under way, 2 of them phase 3. Pulmonary Disease, Chronic Obstructive · Assistance Publique - Hôpitaux de Paris.

Planned enrollment
2nd of 17
386 · median 120
Started
2026
with 2 others
Phase 3
3 of 21
2 open now
Registered
19th of 21
by date

Among the 21 studies in Pulmonary Disease, Chronic Obstructive by Assistance Publique - Hôpitaux de Paris, this one is the 2nd largest by planned enrollment of the 17 interventional ones that give a count, is one of 3 that started in 2026, is one of 3 in phase 3, and was the 19th registered.

Pulmonary Disease, Chronic Obstructive

5,529 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

7 of the 21 studies in Pulmonary Disease, Chronic Obstructive by Assistance Publique - Hôpitaux de Paris are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

Who these studies take

Of the 560 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 30 take children under 18; 88 take healthy volunteers.

This study: 18 Years to 84 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Pulmonary Disease, Chronic Obstructive by Assistance Publique - Hôpitaux de Paris, or all of them as a file.
02

Study summary

Chronic obstructive pulmonary disease (COPD) is a major public health problem with 212.3 million prevalent cases of COPD worldwide and 3.3 million deaths related to COPD in 2019. Obstructive sleep apnoea (OSA) is the most common sleep disordered breathing. It is estimated that almost 1 billion adults have OSA worldwide.

Given the increasing prevalence of obesity, co-morbid OSA is frequently seen in patients with COPD. Co-morbid OSA has been shown to increase mortality, to reduce quality of life and to favour acute exacerbation of COPD. For those admitted for a life-threatening exacerbation of COPD requiring an intensive care admission for acute hypercapnic failure, they are more likely to get readmitted. For those admitted for an acute exacerbation in any ward, they are more likely to be re-admitted for another exacerbation within 180-days if their OSA is not treated.

Unfortunately, data regarding the best management of OSA in patients with co-morbid COPD are lacking as they were often excluded from clinical trials involving patients with COPD. Therefore, CPAP or NIV are administered without scientific evidence establishing which treatment is the most appropriate.

Read the detailed description

Patients admitted for a severe exacerbation of COPD that required NIV or invasive ventilation or high flow therapy will be screened for the trial once they reach clinical stability that allow weaning of NIV, invasive ventilation, or high flow therapy.

The screening visit will take place during a standard consultation between 2 days following admission for acute hypercapnic respiratory failure and no later than 30 days following the discharge from the acute ward.

The inclusion visit will be performed no later than 30-days following discharge from the acute ward.

Follow-up visits will be performed at 3, 6 months after inclusion with a +/-14 days window.

Visits will be conducted in the hospital unless patient is unable to attend due to medical condition or healthcare crisis (infectious pandemic for example). In that case, a remote consultation will be performed to retrieve data available without physical attendance.

03

Conditions studied

  • Chronic Obstructive Pulmonary Disease Exacerbation
  • Obstructive Sleep Apnea Exacerbation

Keywords

  • Chronic Obstructive Pulmonary Disease
  • Obstructive Sleep Apnea
  • Continuous Positive Airway Pressure
  • Non-invasive Ventilation
04

Who can participate

Ages eligible
18 Years to 84 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 18 and \< 85 years
  2. Patient with a diagnosis of according to GOLD guidelines
  3. Patient admitted for an acute exacerbation of COPD requiring acute NIV or invasive ventilation or high-flow therapy (pH \<7.35 with PaCO2 >45mmHg/6kPa)
  4. Patient that has been weaned from acute NIV or invasive ventilation or high flow therapy
  5. Patient with an overnight polygraphy or polysomnography performed 2 to 30 days following weaning from acute NIV or invasive ventilation showing an obstructive apneahypopnea index >=15/h. For patients already diagnosed with OSA, results from their prior sleep study will be retrieved. If not accessible, overnight polygraphy or polysomnography will be repeated.
  6. Affiliated to the National Health Patients affiliated or, beneficiary of social security, excluding AME (Aide Médicale d'État)
  7. Patient who has read and understood the information letter and signed the consent form

Exclusion criteria

Exclusion Criteria:

  1. Patient with NIV treatment
  2. Patients who decline any use of NIV or CPAP in the home setting
  3. Significant psychiatric disorder or dementia that would prevent adherence to study protocol
  4. Tobacco use \<10 pack-year
  5. Expected survival \<12 months due to any condition other than .
  6. Patient deprived of liberty by administrative or judicial decision or placed under judicial protection (guardianship or supervision)
  7. Pregnant or breastfeeding women
  8. Patient already involved in an interventional research protocol that would impact the outcome measured in the current protocol.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
386 participants (estimated)

Study arms

  • Experimental
    Non-invasive Ventilation (NIV)

    Patients randomised to the intervention arm will be established on NIV before discharge to home.

    Device: Non-invasive Ventilation (NIV)

  • Active comparator
    Continuous Positive Airway Pressure (CPAP)

    Patients randomised to the control arm will be established on CPAP before discharge to home.

    Device: Continous Positive Airway Pressure (CPAP)

Interventions

  • DeviceNon-invasive Ventilation (NIV)

    Patients will receive a dedicated training for the use of their NIV in the home setting. The training is the same provided in the usual care of patients established on NIV. They will choose a home care provider for the delivery of NIV as per standard care in France. A telemonitoring of adherence to NIV will be performed.

  • DeviceContinous Positive Airway Pressure (CPAP)

    Patients will receive a dedicated training the use of their CPAP in the home setting. The training is the same provided in the usual care of patients established on CPAP. They will choose a home care provider for the delivery of CPAP as per standard care in France. Follow-up of CPAP will be performed according to standard care in France and will therefore include a telemonitoring of adherence to CPAP.

06

What researchers measure

Primary outcomes

  1. Demonstrate the superiority of home NIV versus home CPAP for the reduction of severe exacerbation of COPD or death.

    Reduction of severe exacerbation of COPD or death, defined by the time to occurrence of (i) death from any cause or (ii) hospitalization in relation to severe exacerbation of COPD during a follow up of 12 months after randomization.

    Time frame: 0-12 months from inclusion

Secondary outcomes

  1. Evaluate the benefit of NIV over CPAP regarding control of sleep disordered breathing

    Control of sleep disordered breathing, defined as evolution between baseline and 1 year follow-up of the following combined criteria : * Apnea-hypopnea index (whilst unsupported breathing at baseline and when using the treatment overnight) * 3% Oxygen desaturation index (whilst unsupported breathing at baseline and when using the treatment overnight) * Proportion of time spent with SpO2 \<90% (whilst unsupported breathing at baseline and when using the treatment overnight) * Change in 3% Oxygen desaturation index between baseline at 3- and 6-months follow-up when using the treatment overnight * Proportion of time spent with SpO2 \<90% at 3 months and 6 months when using the treatment overnight.

    Time frame: 0-12 months from inclusion

  2. Quality of life of NIV over CPAP

    HRQOL compared at 3 months follow-up using HRQOL questionnaires.

    Time frame: At month 3

  3. Quality of life of NIV over CPAP

    HRQOL compared at 12 months follow-up using HRQOL questionnaires.

    Time frame: At month 12

  4. Quality of sleep of NIV over CPAP (Pittsburgh Sleep Quality Index).

    Change in quality of sleep will be assessed using quality of sleep evaluation scales (Pittsburgh Sleep Quality Index).

    Time frame: From Day 1 to Day 90

  5. Quality of sleep of NIV over CPAP

    Change in quality of sleep will be assessed using quality of sleep evaluation scales (Epworth Sleepiness Scale).

    Time frame: From Day 1 to Day 90

  6. Quality of sleep of NIV over CPAP (Insomnia Severity Index).

    Change in quality of sleep will be assessed using quality of sleep evaluation scales (Insomnia Severity Index).

    Time frame: From Day 1 to Day 90

  7. Quality of sleep of NIV over CPAP

    Change in quality of sleep will be assessed using the difference from baseline and one-year follow-up using quality of sleep evaluation scales (Pittsburgh Sleep Quality Index).

    Time frame: From Day 1 to Day 365

  8. Quality of sleep of NIV over CPAP

    Change in quality of sleep will be assessed using the difference from baseline and one-year follow-up using quality of sleep evaluation scales (Epworth Sleepiness Scale).

    Time frame: From Day 1 to Day 365

  9. Quality of sleep of NIV over CPAP (Insomnia Severity Index).

    Change in quality of sleep will be assessed using the difference from baseline and one-year follow-up using quality of sleep evaluation scales (Insomnia Severity Index).

    Time frame: From Day 1 to Day 365

  10. Quality of sleep of NIV over CPAP in centres that will perform overnight polysomnography

    Quality of sleep,defined by variations between day 1 and 1 year in objective measures of sleep quality in centres that will perform overnight polysomnography : proportions of light, deep and REM sleep, wake since sleep onset, awakenings, arousals, sleep efficacy, sleep efficiency.

    Time frame: From Day 1 to Day 365

  11. Respiratory function benefit of NIV over CPAP

    Respiratory function defined as change in gas exchange from baseline (Pa02, PaCO2) and 1 year: Arterial blood gas (ABG) will be measured during daytime and will be performed after 30 min on room air).

    Time frame: From Day 1 to Day 365

  12. Respiratory function benefit of NIV over CPAP

    Respiratory function defined as change in Forced Expiratory Volume 1, at 1 year.

    Time frame: At month 12

  13. Exercise capacity benefit of NIV over CPAP

    Exercise capacity defined as change in distance walked during a 6MWT. 6MWT will be performed at discharge and at each follow-up visit. 6MWT will be performed according to ERS guidelines.

    Time frame: At month 3

  14. Exercise capacity benefit of NIV over CPAP

    Exercise capacity defined as change in distance walked during a 6MWT at 1 year. 6MWT will be performed at discharge and at each follow-up visit. 6MWT will be performed according to ERS guidelines.

    Time frame: At month 12

  15. Benefit of compliance and tolerance of NIV over CPAP

    Compliance of the treatment, defined as Daily use / % of day used \>4hours / side effect questionnaire, assessed at each visit.

    Time frame: From Day 1 to Day 90

  16. Benefit of compliance and tolerance of NIV over CPAP

    Compliance of the treatment, defined as Daily use / % of day used \>4hours / side effect questionnaire, assessed at each visit.

    Time frame: From Day 1 to Day 180

  17. Benefit of compliance and tolerance of NIV over CPAP

    Compliance of the treatment, defined as Daily use / % of day used \>4hours / side effect questionnaire, assessed at each visit.

    Time frame: From Day 1 to Day 365

  18. Benefit of NIV over CPAP regarding usefulness of CPAP/NIV data to predict COPD severe acute exacerbation.

    Change in breathing frequency or other extractable parameters that may predict the onset of a severe exacerbation.

    Time frame: At month 12

07

Study locations

1 of 1 sites recruiting
  • Hospital Pitié-Salpêtrière - Sleep unit, R3S Departement
    Paris, 75013, France
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Oct 2029, 40 months after the start.

Of 33 non-industry phase 3 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 56. This study's planned 40 months is close to that.

Counting every sponsor, half of 142 studies reached it within 23 months; a quarter within 14 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 11, 2025
First posted
Jul 2, 2025
StartActual
Jun 3, 2026
Primary completionEst.
Oct 2029
CompletionEst.
Oct 2030
Last update
Jun 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07047092
Responsible party
Sponsor
First posted
Jul 2, 2025
Start date
Jun 3, 2026
Primary completion
Oct 2029 (estimated)
Completion
Oct 2030 (estimated)
Last update
Jun 9, 2026

Study contacts

Maxime PATOUT, MD, PhD
Contact
maxime.patout@aphp.fr
01 42 16 77 09

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion